← Leaderboards
Brent Peter Forester
Mclean Hospital
$10,348,605
Attributed
$19,800,269
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2009–24$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$19,800,269 · 4
By mechanism
R01$18,903,329 · 3
K23$896,940 · 1
Top collaborators
- Fei Du6 shared
- Paul B Rosenberg6 shared
- Georgios Petrides5 shared
Most similar at Mclean Hospital
Same institution · by research overlap
- Fei Du$6,859,154
- Georgios Petrides$10,081,734
- Mei-Hua Hall$4,899,477
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAgingS DiseaseCognitiveAffectCognitionDementiaClinical TrialsEffective TherapyOpen LabelSeveritiesNeurodegenerative DisordersSitePharmaceutical PreparationsStressBehavioralPrimary OutcomeResistanceResponseCaregiver BurdenAgitationBrainCaregiversOral
Grant awards (22)
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia$819,553
R01 · FY2024 · AG
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia$886,282
R01 · FY2023 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$1
R01 · FY2023 · AG · contact PI
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia$886,282
R01 · FY2022 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,324,251
R01 · FY2021 · AG · contact PI
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$992,308
R01 · FY2021 · AG
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia$554,992
R01 · FY2021 · AG
Effect of Covid-19 on Caregivers of Persons with Dementia$446,295
R01 · FY2021 · AG
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia$313,981
R01 · FY2021 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,344,010
R01 · FY2020 · AG · contact PI
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$997,731
R01 · FY2020 · AG
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia$561,552
R01 · FY2020 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,341,700
R01 · FY2019 · AG · contact PI
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,415,140
R01 · FY2018 · AG · contact PI
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$997,674
R01 · FY2018 · AG
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$996,923
R01 · FY2017 · AG
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)$1,024,654
R01 · FY2016 · AG
Cerebral Energy Metabolism in Geriatric Bipolar Depression$179,388
K23 · FY2013 · MH · contact PI
Cerebral Energy Metabolism in Geriatric Bipolar Depression$179,388
K23 · FY2012 · MH · contact PI
Cerebral Energy Metabolism in Geriatric Bipolar Depression$179,388
K23 · FY2011 · MH · contact PI
Cerebral Energy Metabolism in Geriatric Bipolar Depression$179,388
K23 · FY2010 · MH · contact PI
Cerebral Energy Metabolism in Geriatric Bipolar Depression$179,388
K23 · FY2009 · MH · contact PI